Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products, Opportunities and Challenges

Reasons to buy the ‘Antibody-Drug Conjugates (ADC)’ industry analysis report:

• Gain insight into the competitive landscape of leading antibody-drug conjugates (ADC) through this report.
• Get access to SWOT analysis for key marketed and pipeline drugs, clinical benchmark comparisons, key clinical trial analysis, analyst consensus forecasts, and commentary on current and future players.
• Examine the outlook of four key opinion leaders in the US and analyze key opportunities and challenges in the space.
• The report provides commentary on the latest trends in ADC development including payload and linker analysis.

How is our ‘Antibody-Drug Conjugates (ADC)’ report unique from other reports in the market?

Our modality-specific reports answer questions such as:

• What is the future global market value of ADCs in oncology?
• Which cancer types are more likely to receive these therapies?
• What are the clinical benchmarks for currently approved ADCs?
• What are the emergent linkers and payloads for ADCs?
• What is the key opinion leaders’ outlook for the products?
• What are key opportunities and challenges in the area?

We recommend this valuable source of information to anyone involved in:

• ​​​​Pharma and Biotech Companies/Pharmaceutical Industry Suppliers
• Consulting and Professional Services (e.g., Investment Companies, Investment Banks, Equity Companies, etc.)
• Pharma Manufacturers (Innovative, Biotech, Generics, Biosimilars, Rare/Orphan Disease)/ Distributors
• Financial Institutions (Investors in Pharma/Biotech, Pricing Consultancies)/Parallel Trade Organisations
• Healthcare Organisations/Healthcare Technology Leaders and Start-ups

To Get a Snapshot of the Antibody-Drug Conjugates (ADC) Market Report

Download a Free Report Sample

Antibody-Drug Conjugates Market Report Overview

The Antibody-Drug Conjugates market size was $9.2 Billion in 2023. An Antibody-Drug Conjugates (ADC) drug consists of monoclonal antibodies conjugated to a payload via a linker, for the precise targeting of antigen-positive cancer cells. ADCs are developed to target protein receptors with high expression such as HER2, TROP-2, CD22, and others.

There are two cytotoxic payload types predominantly used in ADCs including microtubule inhibitors, and the more potent DNA-damaging payloads such as topoisomerase I inhibitors.

The following are some of the key highlights of the Antibody-Drug Conjugates market:

• The Antibody-Drug Conjugates market will grow significantly by 2029.
• Daiichi’s deruxtecan payload technology has led to HER2-targeting Enhertu, the highest-grossing ADC approved for multiple indications.

Antibody-Drug Conjugates Market Outlook ($Billion)

Buy the Full Report for More Insights on the ADC Market

Download a Free Sample Report

The Antibody Drug Conjugates market research report will aid clients in gaining insight into the competitive landscape of leading antibody-drug conjugates (ADC) in oncology. The report includes a SWOT analysis for key marketed and pipeline drugs, clinical benchmark comparisons, key clinical trial analysis, analyst consensus forecasts, and commentary on current and future players. The report also offers an outlook from four key opinion leaders in the US and analyzes key opportunities and challenges in the space. Additionally, the report provides commentary on the latest trends in ADC development including payload and linker analysis.

The ADC market research report will aid clients in gaining insight into the competitive landscape of leading antibody-drug conjugates (ADC) in oncology. The report includes a SWOT analysis for key marketed and pipeline drugs, clinical benchmark comparisons, key clinical trial analysis, analyst consensus forecasts, and commentary on current and future players. The report also offers an outlook from four key opinion leaders in the US and analyzes key opportunities and challenges in the space. Additionally, the report provides commentary on the latest trends in ADC development including payload and linker analysis.

Antibody-Drug Conjugates (ADC) – Marketed Drugs

The key marketed drugs in the ADC market are Daiichi Sankyo’s Enhertu, Gilead’s Trodelvy, Genmab’s Tivdak, and Rakuten Medical’s Akalux among others.

Daiichi Sankyo’s Enhertu: This drug is considered best-in-class ADC approved in multiple indications where HER2 is prevalent. Its key strength includes a high drug-antibody ratio with eight deruxtecan payload molecules conjugated to each trastuzumab mAb, for a higher antitumor effect. It also has higher efficacy in terms of OS and PFS versus Kadcyla in mHER2 BC.

Antibody-Drug Conjugates (ADC) Market Analysis by Marketed Drugs

Buy the Full Report for More Insights on the Key Marketed Drugs in the ADC Market

Download a Free Sample Report

Antibody-Drug Conjugates (ADC) – Pipeline Drugs

The key pipeline drugs in the ADC market are Ambrx Biopharma’s ARX788, Bispecific ADC Alphamab Oncology’s JSKN003, Daiichi Sankyo & AstraZeneca’s DS-1062, and Daiichi Sankyo’s U-31402 among others.

Daiichi Sankyo’s Enhertu: This is a first-in-class HER3-directed deruxtecan ADC product. The ADC received breakthrough designation and priority review of its BLA from the FDA for 3L+ EGFR mutated NSCLC.

Antibody-Drug Conjugates (ADC) Market Analysis by Pipeline Drugs

Buy the Full Report for More Insights on the Key Pipeline Drugs in the ADC Market

Download a Free Sample Report

Antibody-Drug Conjugates (ADC) – Competitive Landscape

The key players in the ADC market are Daiichi Sankyo, Pfizer, Roche, AstraZeneca, Hengrui Medicine, and AbbVie among others.

Daiichi Sankyo Co Ltd: Daiichi Sankyo is headquartered in Tokyo, Japan. It is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over-the-counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia.

Antibody-Drug Conjugates (ADC) Market Analysis by Players

Buy the Full Report for More Insights on the Key ADC Players

Download a Free Sample Report